Last reviewed · How we verify

NCT03549130

A Pivotal Study to Assess the Effectiveness of Nasal Dilator (Breathe Right Nasal Strips)

Completed Phase 2 Results posted Last updated 25 September 2018
What this trial tests

Phase 2 trial testing Breathe Right Tan (small/medium) nasal strips in Congestion, Nasal in 130 participants. Completed in 17 February 2011.

Timeline
4 November 2010
Primary endpoint
17 February 2011
17 February 2011

Quick facts

Lead sponsorGlaxoSmithKline
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment130
Start date4 November 2010
Primary completion17 February 2011
Estimated completion17 February 2011
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

18 and older, any sex, with Congestion, Nasal. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change From Baseline in Mean Average Score of Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) for Each Domain Problems (Sleep, Sleep Time, Symptoms on Waking in the Morning, and Practical Problems) at Day 7 Primary · At baseline and Day 7

Participants scored all the domains of NRQLQ using same 7 points scales where 0=Not troubled and 6=extremely troubled. Domains: Sleep problems (difficulty getting sleep, unable to get a good night sleep or wake up during the night, restless \[tossing and turning\] and having to get up because stuffy nose or to blow nose using the score, scores range: Min-Max \[0-24\]); Sleep time problems (Nasal congestion or stuffy nose, sinus pressure or pain, runny nose, post-nasal drip \[drainage down back of nose/throat\], and headache, scores range: 0- 30); Symptoms on waking in the morning (Feel tired a

Sleep Problems
GroupValue95% CI
Active Nasal Strip Group-4.94-5.85 – -4.02
Placebo Nasal Strip Group-4.17-5.09 – -3.25
Sleep Time Problems
GroupValue95% CI
Active Nasal Strip Group-6.30-7.46 – -5.14
Placebo Nasal Strip Group-4.51-5.67 – -3.34
Symptoms on waking in the morning
GroupValue95% CI
Active Nasal Strip Group-6.49-7.55 – -5.44
Placebo Nasal Strip Group-4.87-5.93 – -3.80
Practical problems
GroupValue95% CI
Active Nasal Strip Group-2.98-3.70 – -2.27
Placebo Nasal Strip Group-2.28-3.00 – -1.56
Change From Baseline in Mean Average Score of Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) for Each Domain Problems (Sleep, Sleep Time, Symptoms on Waking in the Morning, and Practical Problems) at Day 14 Primary · At Baseline and Day 14

Participants scored all the domains of NRQLQ using same 7 points scales where 0=Not troubled and 6=extremely troubled. Domains: Sleep problems (difficulty getting sleep, unable to get a good night sleep or wake up during the night, restless \[tossing and turning\] and having to get up because stuffy nose or to blow nose using the score, scores range: Min-Max \[0-24\]); Sleep time problems (Nasal congestion or stuffy nose, sinus pressure or pain, runny nose, post-nasal drip \[drainage down back of nose/throat\], and headache, scores range: 0- 30); Symptoms on waking in the morning (Feel tired a

Sleep Problems
GroupValue95% CI
Active Nasal Strip Group-6.34-7.31 – -5.36
Placebo Nasal Strip Group-5.87-6.85 – -4.89
Sleep Time Problems
GroupValue95% CI
Active Nasal Strip Group-7.30-8.47 – -6.12
Placebo Nasal Strip Group-6.32-7.50 – -5.15
Symptoms on Walking in the Morning
GroupValue95% CI
Active Nasal Strip Group-7.25-8.28 – -6.23
Placebo Nasal Strip Group-6.54-7.56 – -5.52
Practical Problems
GroupValue95% CI
Active Nasal Strip Group-3.47-4.17 – -2.77
Placebo Nasal Strip Group-2.66-3.36 – -1.95
Change From Baseline in Mean Average Score for All the Four Questions of Domain Symptoms on Waking in the Morning of Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) at Day 7 Primary · At Baseline and Day 7

Participants scored for domain Symptoms on waking in the morning of NRQLQ using 7 points scale: 0=not troubled, 1=hardly troubled at all, 2=somewhat troubled, 3= moderately troubled, 4=quite a bit troubled, 5=very troubled, 6=extremely troubled. Questionnaire for this domain included: Feel tired and unrefreshed, nasal congestion or stuffy nose, congestion in sinuses, takes time to clear night time drainage after waking up. Lower scores indicate improvement in the rhinitis symptoms

Feel Tired and Unrefreshed
GroupValue95% CI
Active Nasal Strip Group-1.40-1.70 – -1.10
Placebo Nasal Strip Group-1.15-1.45 – -0.84
Nasal congestion or stuffy nose
GroupValue95% CI
Active Nasal Strip Group-1.71-2.00 – -1.43
Placebo Nasal Strip Group-1.34-1.63 – -1.05
Congestion in sinuses
GroupValue95% CI
Active Nasal Strip Group-1.59-1.90 – -1.28
Placebo Nasal Strip Group-1.04-1.36 – -0.73
Takes time to clear nighttime drainage
GroupValue95% CI
Active Nasal Strip Group-1.80-2.13 – -1.47
Placebo Nasal Strip Group-1.33-1.66 – -1.00
Change From Baseline in Mean Average Score for All the Four Questions of Domain Symptoms on Waking in the Morning of Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire at Day 14 Primary · At Baseline and Day 14

Participants scored for domain Symptoms on waking in the morning of NRQLQ using 7 points scale: 0=not troubled, 1=hardly troubled at all, 2=somewhat troubled, 3= moderately troubled, 4=quite a bit troubled, 5=very troubled, 6=extremely troubled. Questionnaire for this domain included: Feel tired and unrefreshed, nasal congestion or stuffy nose, congestion in sinuses, takes time to clear night time drainage after waking up. Lower scores indicate improvement in the rhinitis symptoms

Feel Tired and Unrefreshed
GroupValue95% CI
Active Nasal Strip Group-1.65-1.92 – -1.39
Placebo Nasal Strip Group-1.46-1.72 – -1.20
Nasal congestion or stuffy nose
GroupValue95% CI
Active Nasal Strip Group-1.96-2.26 – -1.67
Placebo Nasal Strip Group-1.82-2.11 – -1.52
Congestion in sinuses
GroupValue95% CI
Active Nasal Strip Group-1.71-2.00 – -1.42
Placebo Nasal Strip Group-1.70-1.99 – -1.41
Takes time to clear nighttime
GroupValue95% CI
Active Nasal Strip Group-1.93-2.26 – -1.60
Placebo Nasal Strip Group-1.56-1.89 – -1.24
Number of Participants Showing Improvement for Each Domain Problems (Sleep, Sleep Time, Symptoms on Waking in the Morning, and Practical Problems) of Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire at Day 7 Primary · At Day 7

Participants scored all the domains of NRQLQ using 7 points scale,0=Not troubled,1=hardly troubled at all,2=somewhat troubled,3=moderately troubled, 4=quite a bit troubled,5=very troubled,6=extremely troubled.Sleep problems (difficulty getting sleep,unable to get good night sleep/wake up during night, restless \[tossing and turning\],having to get up because stuffy nose or blow nose using score,scores range:Min-Max\[0-24\]),Sleep time problems(Nasal congestion or stuffy nose,sinus pressure or pain,runny nose,post-nasal drip\[drainage down back of nose/throat\],headache,scores range:0-30);Sympt

Improvement:all of the items in sleep problems
GroupValue95% CI
Active Nasal Strip Group20
Placebo Nasal Strip Group21
Improvement:any of the items in sleep problems
GroupValue95% CI
Active Nasal Strip Group59
Placebo Nasal Strip Group61
Improvement:all of items in sleep time problems
GroupValue95% CI
Active Nasal Strip Group21
Placebo Nasal Strip Group17
Improvement:any of items in sleep time problems
GroupValue95% CI
Active Nasal Strip Group58
Placebo Nasal Strip Group61
Improvement:all of items in symptom on walking(AM)
GroupValue95% CI
Active Nasal Strip Group37
Placebo Nasal Strip Group28
Improvement:any of items in symptom on walking(AM)
GroupValue95% CI
Active Nasal Strip Group60
Placebo Nasal Strip Group58
Improvement:all of the items in practical problems
GroupValue95% CI
Active Nasal Strip Group9
Placebo Nasal Strip Group12
Improvement:any of the items in practical problems
GroupValue95% CI
Active Nasal Strip Group53
Placebo Nasal Strip Group48
Number of Participants Showing Improvement for Each Domain Problems (Sleep, Sleep Time, Symptoms on Waking in the Morning, and Practical Problems) of Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire at Day 14 Primary · At Day 14

Participants scored all the domains of NRQLQ using 7 points scale,0=Not troubled,1=hardly troubled at all,2=somewhat troubled,3=moderately troubled, 4=quite a bit troubled,5=very troubled,6=extremely troubled.Sleep problems (difficulty getting sleep,unable to get good night sleep/wake up during night, restless \[tossing and turning\],having to get up because stuffy nose or blow nose using score,scores range:Min-Max\[0-24\]),Sleep time problems(Nasal congestion or stuffy nose,sinus pressure or pain,runny nose,post-nasal drip\[drainage down back of nose/throat\],headache,scores range:0-30);Sympt

Improvement:all of the items in sleep problems
GroupValue95% CI
Active Nasal Strip Group31
Placebo Nasal Strip Group34
Improvement:any of the items in sleep problems
GroupValue95% CI
Active Nasal Strip Group59
Placebo Nasal Strip Group60
Improvement:all of items in sleep time problems
GroupValue95% CI
Active Nasal Strip Group24
Placebo Nasal Strip Group26
Improvement:any of items in sleep time problems
GroupValue95% CI
Active Nasal Strip Group60
Placebo Nasal Strip Group62
Improvement:all of items in symptom on walking(AM)
GroupValue95% CI
Active Nasal Strip Group35
Placebo Nasal Strip Group39
Improvement:any of items in symptom on walking(AM)
GroupValue95% CI
Active Nasal Strip Group62
Placebo Nasal Strip Group63
Improvement:all of the items in practical problems
GroupValue95% CI
Active Nasal Strip Group14
Placebo Nasal Strip Group13
Improvement:any of the items in practical problems
GroupValue95% CI
Active Nasal Strip Group55
Placebo Nasal Strip Group51

Adverse events — posted to ClinicalTrials.gov

Time frame: Approximately 21 days. Reporting threshold: 1%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Active Nasal Strip Group
Serious: 0/64 (0%)
Deaths: 0/64
Placebo Nasal Strip Group
Serious: 0/64 (0%)
Deaths: 0/64
Other adverse events (9 terms — click to expand)

ReactionSystemActive Nasal Strip GroupPlacebo Nasal Strip Group
APPLICATION SITE PRURITUSGeneral disorders
APPLICATION SITE DISCOLOURATIONGeneral disorders
APPLICATION SITE ERYTHEMAGeneral disorders
APPLICATION SITE IRRITATIONGeneral disorders
INFLUENZA LIKE ILLNESSGeneral disorders
NASAL CONGESTIONRespiratory, thoracic and mediastinal disorders
NASAL DISCOMFORTRespiratory, thoracic and mediastinal disorders
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations

Data from ClinicalTrials.gov NCT03549130 adverse events section.

Sponsor's own description

This randomized, double-blind, parallel group, placebo-controlled study assessed subjective measures of nasal airway breathing immediately after application in the morning upon awakening after use of breathe right nasal strips (BRNS). Participants who met the entrance criteria, were currently suffering from nasal congestion, reported trouble with their sleep and had baseline nasal openness scores at bedtime during the qualification phase of ≤ 70 on a 100-point Visual Analogue Scale (VAS) on at least four of seven qualification nights were randomized to one of two treatments for use at home. Participants returned to the study site after 7 and 14 days of nightly nasal strip use, respectively. At the two return visits, a validated subjective questionnaire, the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ), measured response.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Sleep Quality and Congestion with Breathe Right Nasal Strips: Two Randomized Controlled Trials.
    Noss MJ, Ciesla R, Shanga G. · · 2019 · cited 4× · PMID 31209698 · DOI 10.1007/s12325-019-01005-5

Verify or expand the search:

Other trials of Breathe Right Tan (small/medium) nasal strips

Trials testing the same drug.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03549130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing